Transvaginal Mesh Injury Lawsuits: Next C.R. Bard Trial Slated for Dec. 3, Rottenstein Law Group LLP Reports
The next C.R. Bard transvaginal mesh trial is scheduled for Dec. 3 in the U.S. District Court in West Virginia, according to court documents. The Rottenstein Law Group LLP, which represents clients in transvaginal mesh injury lawsuits, reports on updates related to Bard mesh trials, in addition to offering a brief rundown of the multimillion dollar vaginal mesh verdicts to date.Read More
DePuy ASR Lawsuit Settlement News: Johnson & Johnson Agrees to Settle for at Least $2.5 Billion, Notes Rottenstein Law Group LLP
Johnson & Johnson and its subsidiary DePuy Orthopaedics agreed Nov. 19 to a DePuy ASR hip settlement of at least $2.5 billion, according to news reports. The Rottenstein Law Group LLP, a metal-on-metal hip implant law firm, notes that those who underwent revision surgery will be eligible for a settlement, but settlement is not required.Read More
There are six federal case consolidations in U.S. District Court for the Southern District of West Virginia for as many major mesh manufacturers, and bellwether trials have been scheduled for most of them, according to court documents. The Rottenstein Law Group LLP, which represents clients in vaginal mesh lawsuits, notes that the next trial scheduled, which involves C.R. Bard, is coming up on Dec. 3.Read More
Bergen County District Court in New Jersey has deemed a DePuy ASR hip lawsuit “resolved” and removed the matter from its trial calendar, according to court documents. The Rottenstein Law Group LLP, which maintains a comprehensive DePuy settlements informational website, notes that if the case has settled out of court then it will join a growing list of ASR lawsuits similarly resolved.Read More
DePuy ASR Hip Lawsuit News: Settlement Reached in California Hip Case, Rottenstein Law Group LLP Reports
Johnson & Johnson subsidiary DePuy Orthopaedics has agreed to settle a DePuy ASR hip lawsuit before what would have been the first bellwether trial in a California state court consolidation of ASR cases. The Rottenstein Law Group LLP, which maintains the hip implant informational website http://www.depuysettlements.com, notes that the settlement joins a growing list of current and potential ASR settlements.Read More
Heart problems associated with the plaque build-up that cannot be managed by changes in lifestyle, diet and medications may make the person a candidate for a coronary artery bypass, health experts say. There are two main techniques that may be used in performing this procedure, according to the Robotic Surgery Center, with the help of the robotic assistant. The use of the robotic surgical system utilizes the same principles in a laparoscopic surgery wherein both are minimally invasive procedures. Instead of patients having to undergo open heart surgery, they may now have the option to choose between robotic-assisted or laparoscopic surgery.
Findings from a small study moved the Food and Drug Administration (FDA) to raise a couple of red flags concerning the drug Januvia, which might have been associated with pancreatitis and other types of cancer, an online report says. Following a study reported by the JAMA Internal Medicine, FDA has started an investigation whether or not type 2 diabetes drugs Januvia may increase risks of developing pancreatic cancer, according to www medicalnewstoday.com. Januvia is an oral drug produced by Merck & Co to treat type 2 diabetes, but recently has been the center of attention by some Januvia lawyers because of its affiliation with pancreatic cancer.
FDA started questioning the safety of the drug upon receiving a stream of reports and cases of Januvia users reporting they were at risks of developing pancreatic cancer. Indeed, in 2009, the FDA added information to the labels of Januvia about its association with pancreatitis but carefully disclaiming that the drug is still under thorough investigation. Thus, patients must continue taking Januvia unless advised on the contrary by their physicians.
Overall, Januvia may have no compelling evidence of its association to pancreatic cancer but this is definitely something to look into moving forward, says the report.Read More